Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer—where are we now?
Simple Summary The past decade has seen the development and regulatory approval of a
large number of new treatment options for advanced prostate cancer. Despite this, the two …
large number of new treatment options for advanced prostate cancer. Despite this, the two …
Prostate cancer in transgender women: considerations for screening, diagnosis and management
F Crowley, M Mihalopoulos, S Gaglani… - British Journal of …, 2023 - nature.com
Abstract Transgender individuals represent 0.55% of the US population, equivalent to 1.4
million transgender adults. In transgender women, feminisation can include a number of …
million transgender adults. In transgender women, feminisation can include a number of …
GEC-ESTRO ACROP prostate brachytherapy guidelines
This is an evidence-based guideline for prostate brachytherapy. Throughout levels of
evidence quoted are those from the Oxford Centre for Evidence based Medicine …
evidence quoted are those from the Oxford Centre for Evidence based Medicine …
ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer
NS Schmidt-Hegemann, C Zamboglou… - Radiotherapy and …, 2023 - Elsevier
Background and purpose There is no consensus concerning the appropriate use of
androgen deprivation therapy (ADT) during primary and postoperative external-beam …
androgen deprivation therapy (ADT) during primary and postoperative external-beam …
Ultra-hypofractionated radiotherapy for low-and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy
YM Tsang, H Tharmalingam… - Radiotherapy and …, 2021 - Elsevier
Purpose To compare the biochemical control rates (BCRs), late gastrointestinal (GI) and
genitourinary (GU) toxicities in patients with low-and intermediate risk prostate cancer (PCa) …
genitourinary (GU) toxicities in patients with low-and intermediate risk prostate cancer (PCa) …
HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis
GA Viani, CV Arruda, ACA Pellizzon, LI De Fendi - Brachytherapy, 2021 - Elsevier
Purpose The effectiveness and safety of high dose brachytherapy as monotherapy (HDR-
BRT-M) in prostate cancer is limited to retrospective studies. We performed a meta-analysis …
BRT-M) in prostate cancer is limited to retrospective studies. We performed a meta-analysis …
The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer
K Numakura, M Kobayashi, Y Muto, H Sato, Y Sekine… - Current …, 2023 - mdpi.com
A recent approach to radiotherapy for prostate cancer is the administration of high doses of
radiation to the prostate while minimizing the risk of side effects. Thus, image-guided …
radiation to the prostate while minimizing the risk of side effects. Thus, image-guided …
Prostate cancer brachytherapy: SFRO guidelines 2021
Prostate brachytherapy techniques are described, concerning both permanent seed implant
and high dose rate brachytherapy. The following guidelines are presented: brachytherapy …
and high dose rate brachytherapy. The following guidelines are presented: brachytherapy …
A review on the current treatment paradigm in high-risk prostate cancer
Simple Summary Patients with high-risk prostate cancer are usually treated with
combination of radiotherapy and androgen deprivation therapy. However, there has been …
combination of radiotherapy and androgen deprivation therapy. However, there has been …
Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI
YN Zhang, ZG Lu, SD Wang, X Lu, LL Zhu, X Yang… - Cancer Imaging, 2022 - Springer
Background We aimed to assess the clinical value of 18F-PSMA-1007 and 68Ga-PSMA-11
PET/MRI in the gross tumor volume (GTV) delineation of radiotherapy for prostate cancer …
PET/MRI in the gross tumor volume (GTV) delineation of radiotherapy for prostate cancer …